Four Years, One Defence, and the Base-Tier Gap: Inside Parikshit Somani's Trimetazidine Ban

In November 2026, in the old club room at the Rajshahi Tennis Complex, I hand-logged all 44 men's singles entries — name, age, club, first-round opponent. Seven years later I opened that notebook again and asked myself one question: how many of those 44 knew what trimetazidine was?

Zero. How many had ever read the WADA Prohibited List? Zero. How many knew that a meal cooked by a family member could end a career? Zero.

I found the story in the ninth lane, not the final whistle. The parts of Parikshit Somani's four-year ban that are getting the most oxygen — trimetazidine, the Valieva comparison, the words "scientifically implausible" — sit on the top layer of the case. Underneath it sits a question that applies just as cleanly to those 44 entries in Rajshahi: what exactly are we teaching a player who was never taught the rule, by giving him four years for breaking it?

Context: what happened, and what was left unsaid

Somani is 26. His career-high ranking is No. 256 in doubles — that single number is the only performance data point in the entire case file. Last year, at a lower-tier event in Astana, Kazakhstan, a sample returned trimetazidine, an S4-class metabolic modulator on the WADA Prohibited List and banned at all times. His defence was that the substance entered his system through food prepared by a family member.

After an August hearing, the ITIA's independent tribunal rejected that defence — "scientifically implausible," "highly speculative," "unconvincing." The ban announced on Wednesday runs to September 2029, which puts him at roughly 30 on return. Its scope covers not only playing but coaching and even attendance at ITF, ATP, WTA, Grand Slam and national-federation events.

Two comparisons have been pulled in: Kamila Valieva, who received four years for the same substance, and Sun Yang, whose 2026 case also involved trimetazidine.

The first gap shows up right there. The report has a hearing date — August. It has an announcement day — Wednesday. It does not state when the ineligibility clock actually starts, or what happened to the provisional suspension in between. Thirteen years of writing about sport has taught me this pattern holds in three places at once — referees' calls, tribunal reasoning, ranking arithmetic. The verdict gets announced loudly; the mechanism gets whispered. Transparency ends up as a slogan, and the audience is left holding the least complete version of the record.

Core analysis: whose shoulders carry the burden

The least discussed and most ruthless rule in the anti-doping system is the burden of proof on contamination. A player cannot say "it probably came from food." They have to prove the specific source: which meal, prepared by whom, in what quantity, on what date, verified by which laboratory.

Whether a contamination defence survives depends on how much scientific infrastructure stands behind the player — and at the base tier, that infrastructure is effectively zero.

In Somani's case, the tribunal's language suggests the argument failed not only legally but scientifically. That is where the Valieva comparison is genuinely relevant — though not for the reason most readers assume. The two cases do not share facts. They share the architecture of the argument. Same substance, same food-contamination narrative, same outcome: four years. Tribunals are now viewing trimetazidine food-contamination stories through a specific, tightening lens of scepticism. This is not an isolated ruling; it is a line.

The reporting that placed Somani beside Valieva makes the two cases read as factually equivalent. They are not — only the defence strategy rhymes. Missing that distinction leads straight to a wrong conclusion.

Second, the scope of the sanction. Four years looks enormous in a headline, but the real damage is not in the number, it is in the footprint. Being barred from playing and being barred from coaching and attending events are two different punishments. The first stops a career; the second stops an identity. Players making the transition out of competition often build that bridge through coaching or federation work. Somani's bridge is closed for four years too.

Third, the tier. Astana, Kazakhstan — the event itself is not even named. I have spent years holding Challenger and ITF draw sheets, and this is the level where testing density is thinnest, medical advice is least professional, and families usually handle nutrition and medication. His defence — food from a family member — is not a convenient excuse. It is an accurate picture of how the base tier operates, which is also, unfortunately, its riskiest operating model.

Contrarian angle: what the headline hides

Let me do an uncomfortable piece of arithmetic that newsrooms will not do. What does a career-high doubles ranking of No. 256 at age 26 actually mean? It means well below the top-100 cut, outside the main-tour prize-money structure, and — for most players at that level — financially at break-even or worse. The four years will cost him less in absolute terms than four years would cost a top-100 player, simply because there was less to lose.

The cruelty of this case is not wasted talent; it is a door closing before the possibility was even tested.

Second uncomfortable calculation: Protected Ranking. Players get ranking relief for injury layoffs. They generally do not get it for doping bans. In September 2029, Somani restarts from zero, through qualifying. For a 30-year-old, that is not a ranking rebuild — it is a demand to prove himself all over again, and that specific demand is one of the biggest drivers of re-injury and psychological collapse. I have watched enough comebacks to know the opponent is rarely the player across the net. It is the condition.

Third: India's tour-level picture does not change because of this ban. Indian men's tennis lacks a deep top-100 base, so the suspension of a fringe doubles player is nearly invisible in national strength terms. Nobody will write that, because the "national loss" frame draws more readers.

And the point that matters most from where I sit: in the India-Bangladesh tennis region, the real anti-doping crisis is not at the top. It is at the very bottom — where players are never tested, never educated, and then handed four years the moment they are caught.

While researching my 2026 documentary "Dormant Court," I dug through Bangladesh Tennis Federation files — founded 2026, ITF member since 2026, Davis Cup debut in 2026, the 2026 Asia/Oceania semi-final run. That archive contains no record of an anti-doping education programme. In 2026, I stood courtside at the J30 in Dhaka during Zarif Abrar's title run — no junior was handed a prohibited list. If we are debating a 2029 ban now, where does the next 26-year-old learn, and who teaches him?

Takeaway

Somani's case is a signal about enforcement, not about stardom: tennis now watches the very bottom of its pyramid, and tribunals are getting progressively harder on trimetazidine food-contamination defences. A Court of Arbitration for Sport appeal is possible, though success on the same evidence looks unlikely.

I am filing the record the way I filed the silence — frame by frame. A dormant court still whispers if you run the tape back. The question is not about Somani. It is about those 44 players, and the generation after them, whose names are on draw sheets and not on prohibited lists. Who reads them the rule first — or do we wait for another Wednesday, and another four years?